Ther Adv Urol 2020 Jan-Dec;12:1756287220974130. Epub 2020 Dec 18.
Department of Urology, Yonsei University Wonju College of Medicine, 20Ilsan-ro, Wonju-si, Kangwon-do, 220-701, South Korea.
Background: The aim of this study was to evaluate the change in lower urinary tract symptoms and quality of life (QoL) after combination therapy of solifenacin and mirabegron in patients with benign prostatic hyperplasia presenting with persistent storage symptoms after treatment with tamsulosin.
Material & Methods: We evaluated the International Prostatic Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS), prostate-specific antigen, prostate volume, peak flow rate (Qmax), and post-voided residual volume (PVR) before and after treatment. Patients showing baseline OABSS ⩾3 were included and treated with tamsulosin 0. Read More